Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

Authors :: Rui-Hua Xu
Yu-Hong Li
Feng-Hua Wang
Dong-Sheng Zhang
Hui-Yan Luo
Shuang-Zhen Chen
Si-Mei Shi
Ying Guo
Hong Qiu
Zhi-Qiang Wang
Zong-Jiong Mai
Ying Jin
Xiang-Yuan Wu
Zeng-Qing Guo
Qing-Feng Zou
Ying Yuan
Jie-Er Ying
Fu-Xiang Zhou
Zhi-Xiang Zhuang
Yi-Chen Yao
Zhi-Gang Ma
Xiao-Hua Hu
Wei Wang
Yan Zhang
Wei-Jia Fang
Xiang-Lin Yuan
Yan-Qiao Zhang
Jian Xiao
Ming-Ming He
Feng Wang
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

Full Text Access

Tools